infigratinib
infigratinib: sourced relationships with 1 company · 2 clinical trials tracked.
infigratinib evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could infigratinib → LIANY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| LianBio (LIANY) gastric cancer and other FGFR-driven tumors | Phase 2 |
Clinical Trial Registry Records (2)
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Hypochondroplasia: ACCEL OLE
Primary endpoint: Incidence of treatment emergent adverse events (TEAE) and serious TEAE
A Phase 1B Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Primary endpoint: Number of Dose-limiting Toxicities (DLTs)
Frequently asked questions
Which companies have sourced relationships with infigratinib?
infigratinib has dated SEC/FDA relationship records for LianBio.
How many clinical trials involve infigratinib?
BioSniper tracks 2 clinical trials involving infigratinib.